---
document_datetime: 2023-09-21 21:10:37
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/crixivan-epar-procedural-steps-taken-authorisation_en.pdf
document_name: crixivan-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5114459
conversion_datetime: 2025-12-24 14:26:32.577444
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

<!-- image -->

- The CPMP, in the light of the overall data submitted and the scientific discussion held within the Committee,  issued  on  20  June  1996  a  positive  opinion  for  granting  a  Marketing Authorisation for Crixivan.

The  company  Merck  Sharp  &amp;  Dohme  Ltd,  Hertford  Road,  Hoddesdon  Hertfordshire  EN11  9BU, United Kingdom submitted on 1 March 1996 an application for Marketing Authorisation to the EMEA for Crixivan capsules 200 mg and 400 mg, through the centralised procedure. After agreement by the CPMP on 21-22 November 1995, this medicinal product was referred to List B in the Annex of the Council Regulation EEC No 2309/93; indent 7, as it contains a new active substance. The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Prof. K. Strandberg Co-Rapporteur: Dr. H. Pittner Licensing status: Crixivan  has  received  a  Marketing  Authorisation  in  several  non-EU  countries  including  the  United States on 13 March 1996 and in Brazil on 1 April 1996. 2. Steps taken for the assessment of the product · An  application  for  Marketing  Authorisation  for  Crixivan  was  submitted  to  the  EMEA  on 1 March 1996. The procedure started on 13 March 1996. · During the April CPMP Meeting 1996, it was agreed to perform a Good Manufacturing Practice inspection on the American manufacturing facility (USA, Virginia) for the finished medicinal product. · The preliminary clinical Rapporteur's assessment report was circulated to all CPMP Members on 15-18 April 1996. · The  preliminary  clinical  Co-Rapporteur's  assessment  report  was  circulated  on  15-18  April 1996. · The  Co-Rapporteur's  initial  assessment  report  was  circulated  to  all  CPMP  Members  on 23 April 1996. The Rapporteur's initial assessment report was circulated to all CPMP Members on 26 April 1996. · An  inspection  of  the  manufacturing  site  (Merck  Manufacturing  Division,  Elkton,  Virginia, USA)  of  the  finished  medicinal  product  was  carried  out  by  the  Health  Inspectorate  for Medicines, the Netherlands, on 23-25 April 1996. · A break-out session between the Rapporteur's and the Co-Rapporteur's assessment teams was held on 20 May 1996 to prepare the consolidated list of questions. · The CPMP consolidated list of questions was sent to the company on 22 May 1996. · The responses to the consolidated list of questions were provided on 31 May 1996. · The joint Rapporteur and Co-Rapporteur's assessment report on the responses provided by the applicant was sent to all CPMP Members on 6 June 1996. A  hearing  with  the  applicant  was  held  on  18  June  1996  during  the  June  CPMP  meeting  to address the strategy of ongoing clinical studies. The applicant submitted on 19 June 1996 their letter of commitments for providing information on clinical aspects as part of the reassessment of the benefit/risk profile. The applicant agreed to provide additional information regarding quality aspects. Medicinal Product no longer authorise

<div style=\"page-break-after: always\"></div>

- Following  a  rapid  alert  from  France  on  14  June  1996  drawing  attention  to  reports  of spontaneous bleeding in haemophiliac patients involved in the 'compassionate use (Autorisation Temporaire d'Utilisation)' programme,  the  CPMP,  during  its meeting of 16-17 July 1996 agreed to revise the opinion adopted on 20 June 1996. In the revised opinion warnings have been introduced into the Summary of Product Characteristics and in the Package Leaflet  in  the  light  of  the  information  available.  The  wordings  proposed  by  the  CPMP  have been  discussed  between  the  Chairman  of  the  Committee  and  the  companies  involved  in  the marketing of protease inhibitors. An agreement on the warnings to be introduced was reached on Monday 22 July 1996.

<!-- image -->